---
layout: page
permalink: /news/
title: news
description: 
nav: true
nav_order: 6
---



#### television, radio, and podcasts

Feb 2025: [Weight loss drugs may become harder to get. What does that mean for patients?](https://www.wbur.org/onpoint/2025/02/28/wegovy-ozempic-shortage-fda-compounding-pharmacy). WBUR [NPR station].

Sept 2024: [Recap of Novo Nordisk Hearing](https://www.bbc.co.uk/sounds/play/w172zb92nd09p3s). BBC World Service.

Sept 2024: [What the Maker of Ozempic Doesn't Want You to Know: It's Bankrupting America](https://www.youtube.com/watch?v=JqHmvMjXuro). More Perfect Union.

   <iframe width="560" height="315" src="https://www.youtube.com/embed/JqHmvMjXuro?start=275" frameborder="0" allowfullscreen></iframe>

June 2024: [Sanders calls on Ozempic maker to lower price of drug](https://edition.cnn.com/2024/06/18/politics/video/the-lead-bernie-sanders-wegovy-ozempic-prices-helthcare-isarel-gaza-war-jake-tapper). CNN interview with Senator Bernie Sanders.

Apr 2024: [How one state is trying to make weight loss drugs cheaper](https://www.nbcnews.com/health/health-news/one-state-trying-make-weight-loss-drugs-cheaper-rcna148997). NBC.

Apr 2024: [American people are 'sick and tired' of being 'ripped off by drug companies’](https://www.msnbc.com/ana-cabrera-reports/watch/bernie-sanders-american-people-are-sick-and-tired-of-being-ripped-off-by-drug-companies-208144965580).  MSNBC interview with Senator Bernie Sanders.

Mar 2024: [New study details costs of making diabetes drugs](https://www.youtube.com/watch?v=AQXwtb2_da8). CNBC "Fast Money".

   <iframe width="560" height="315" src="https://www.youtube.com/embed/AQXwtb2_da8" frameborder="0" allowfullscreen></iframe>
   
Sept 2023: [Hearing: Legislative Proposals to Prevent and Respond to Generic Drug Shortages](https://www.c-span.org/video/?530442-1/house-hearing-generic-drug-supply).  C-SPAN.

Sept 2022: [California plans to make its own insulin and sell it super-cheap. Really.](https://armandalegshow.com/episode/california-making-insulin/) An Arm and a Leg.

Jan 2022: [Report: La vigile attesa](https://www.raiplay.it/video/2022/01/La-vigile-attesa---Report-31012022-667606d9-ff1e-4323-9add-0669ab47e532.html?wt_mc=2.www.wzp.raiplay_dati). RAI (Radiotelevisione italiana).

Oct 2021: [KNX In Depth (live LA current affairs radio show)](https://radiocut.fm/audiocut/molnupiravir-cost-based-estimated-generic-prices). KNX Radio


---

#### print and online media

<div style="text-align: center;">
    <h5>2025</h5>
</div>

Apr 17: [Patients of rare disease welcome prospect of dramatic slash in price of drug](https://timesofindia.indiatimes.com/india/patients-of-rare-disease-welcome-prospect-of-dramatic-slash-in-price-of-drug/articleshow/120382558.cms). The Times of India.

Apr 16: [Pharma companies expected to absorb any tariff hit in short term](https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-companies-expected-absorb-any-tariff-hit-short-term-2025-04-16/). Reuters.

Mar 26: [Indian company can now make Spinal Muscular Atrophy drug, High Court cites public interest](https://indianexpress.com/article/cities/delhi/delhi-hc-sma-drug-risdiplam-natco-swiss-pharma-roche-9905857/). Indian Express.

Mar 24: [Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patent](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/delhi-hc-rejects-roches-plea-to-block-natco-pharma-on-risdiplam-patent/articleshow/119435137.cms). Economic Times.

Mar 18: [Balancing Health Rights and Resource Constraints: The Dilemma of Rare Disease Treatment in India](https://genevahealthfiles.substack.com/p/balancing-health-rights-and-resources-rare-diseases-india-resolution-access-to-medicines-cost-intellectual-property-supreme-court-kerala-seba). Geneva Health Files.

Mar 13: [Trump’s Tariffs Threaten US Drug Prices](https://observervoice.com/trumps-tariffs-threaten-us-drug-prices-102880/). Observer Voice.

Mar 12: [US tariffs on India will be a bitter pill to swallow](https://www.bbc.com/news/articles/ckg8ke45gq0o). BBC.

Feb 28: [High cost patented drugs a crippling blow to those with rare diseases](https://timesofindia.indiatimes.com/india/high-cost-patented-drugs-a-crippling-blow-to-those-with-rare-diseases/articleshow/118627756.cms). The Times of India.

Feb 12: [For Many, Weight-Loss Drugs Are Pricey. Expanding Access Is Hard](https://undark.org/2025/02/12/expanding-access-glp1/). Undark Magazine.

Feb 2: [Yale experts weigh in on U.S. WHO exit](https://yaledailynews.com/blog/2025/02/02/yale-experts-weigh-in-on-u-s-who-exit/). Yale News.

Jan 25: [People with spinal muscular atrophy demand urgent action from the Centre to reduce medicine costs](https://www.thehindu.com/sci-tech/health/experts-seek-affordable-access-to-medicines-for-treating-spinal-muscular-atrophy/article69072252.ece). The Hindu.

Jan 20: [A Rare Invocation for a Rare Disease?: Government Urged to Invoke Section 100, Patents Act for Rare Disease Medicine.](https://spicyip.com/2025/01/a-rare-invocation-for-a-rare-disease-government-urged-to-invoke-section-100-patents-act-for-rare-disease-medicine.html) SpicyIP 

Jan 8: [Experts seek affordable access to medicines for treating Spinal Muscular Atrophy](https://www.thehindu.com/sci-tech/health/experts-seek-affordable-access-to-medicines-for-treating-spinal-muscular-atrophy/article69072252.ece). The Hindu.

<div style="text-align: center;">
    <h5>2024</h5>
</div>

Nov 10: [How many patients must die to pay the debt to drug innovation: Interview with Dr Melissa Barber](https://timesofindia.indiatimes.com/home/sunday-times/all-that-matters/how-many-patients-must-die-to-pay-the-debt-to-drug-innovation-dr-melissa-barber/articleshow/115122367.cms). Times of India. [Print version](https://scholar.harvard.edu/sites/scholar.harvard.edu/files/melissabarber/files/print_times_of_india.jpg?m=1734699873)

Nov 6: [Patient health body opposes move to bar generic SMA drug](https://www.hindustantimes.com/india-news/patient-health-body-opposes-move-to-bar-generic-sma-drug-101730833683271.html). Hindustan Times.

Nov 6: [Swiss firm Roche bid to prevent India’s Natco Pharma from introducing cheap spinal drug](https://www.telegraphindia.com/india/swiss-firm-roche-bid-to-prevent-indias-natco-pharma-from-introducing-cheap-spinal-drug/cid/2060900). The Telegraph.

Nov 6: [Patents and high price barriers: patients with rare diseases face woes to access medicines from MNCs](https://health.economictimes.indiatimes.com/news/industry/patents-and-high-price-barriers-patients-with-rare-diseases-face-woes-to-access-medicines-from-mncs/114998204). The Economic Times.

Nov 5: [How a Rs 72 lakh drug for a rare genetic disease could cost just Rs 3,000](https://www.indiatoday.in/health/story/how-rare-genetic-disease-sma-drug-risdiplam-priced-at-rs-72-lakh-can-be-developed-in-rs-3000-2627702-2024-11-05). India Today.

Oct 28: [Rs 72 lakh/year rare-disease drug can be made for Rs 3,000/year, High Court told](https://timesofindia.indiatimes.com/india/rs-72-lakh/year-rare-disease-drug-can-be-made-for-rs-3000/year-hc-told/articleshow/114666406.cms). Times of India.

Oct 28: [Could a Rs 72 lakh drug cost just Rs 3,000? A 24-year-old's courtroom revelation.](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/could-a-rs-72-lakh-drug-cost-just-rs-3000-a-24-year-olds-courtroom-revelation/articleshow/114679955.cms]=). Economic Times.

Oct 7: [Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries](https://www.nytimes.com/2024/10/02/health/lenacapavir-hiv-shot-prep.html). New York Times.

Sept 24: [Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers](https://www.usatoday.com/story/news/health/2024/09/24/senate-hearing-novo-nordisk-ceo-ozempic-wegovy-prices/75348020007). USA Today.

Sept 24: [Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad](https://www.washingtonpost.com/business/2024/09/24/ozempic-weight-loss-price-sanders). Washington Post.

Sept 23: [Analysts say market forces will lower cost of obesity drugs](https://rollcall.com/2024/09/23/analysts-say-market-forces-will-lower-cost-of-obesity-drugs). Roll Call.

July 5: [Health—if you can afford it](https://www.yalealumnimagazine.com/articles/5891-health-if-you-can-afford-it). Yale Alumni Magazine.

July 2: [President Biden: Novo Nordisk, Eli Lilly must stop ripping off Americans with high drug prices](https://eu.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007). USA Today.

June 26: [Wegovy And Ozempic Are Overpriced By 400-500% — Here’s A Quick Solution](https://www.forbes.com/sites/robertpearl/2024/06/24/weight-loss-drugmakers-are-overcharging-by-400-heres-a-quick-solution). Forbes.

May 2: [What is behind the insulin shortage in the US?](https://www.aljazeera.com/economy/2024/5/2/what-is-behind-the-insulin-shortage-in-the-us). Al Jazeera.

Apr 29: [MSF publishes clinical trial cost, challenges pharma to do the same](https://timesofindia.indiatimes.com/home/sunday-times/msf-publishes-clinical-trial-cost-challenges-pharma-to-do-the-same/articleshow/109671392.cms). The Times of India.

Apr 25: [Cost of developing new drugs may be far lower than industry claims, trial reveals](https://www.theguardian.com/global-development/2024/apr/25/cost-of-developing-new-drugs-may-be-far-lower-than-industry-claims-trial-reveals). The Guardian.

Apr 24: [This Is What a Miracle Drug Looks Like, and It Costs Only \$5 to Make](https://www.nytimes.com/2024/04/24/opinion/ozempic-wegovy-weight-glp1.html). The New York Times.

Apr 24: [Diabetes Medication Can Be Manufactured at Lower Cost, New Study Says](https://medicine.yale.edu/internal-medicine/news-article/diabetes-medication-lower-costs). Yale News.

Apr 16: [«Fett-weg»-Spritzen könnten statt 150 nur 20 Franken kosten](https://www.infosperber.ch/gesundheit/fett-weg-spritzen-koennten-statt-150-nur-20-franken-kosten). Infosperber.

Apr 6: [El “estilo de vida europeo” que asfixia la salud pública de África](https://elpais.com/planeta-futuro/2024-04-06/el-estilo-de-vida-europeo-que-asfixia-la-salud-publica-de-africa.html). El Pais.

Apr 2: [MSF denuncia los "desorbitados" precios de los nuevos medicamentos para la diabetes](https://www.larazon.es/sociedad/msf-denuncia-desorbitados-precios-nuevos-medicamentos-diabetes_20240402660b83630999030001ca062a.html). La Razón (Spain).

Apr 1: [MSF study reveals global double standard in diabetes care](https://www.developmentaid.org/news-stream/post/177039/msf-global-double-diabetes-care). Development Aid.

Mar 29: [Research flags excessive 'profiteering' on diabetes drugs by sections of pharmaceutical industry](https://www.telegraphindia.com/health/research-flags-excessive-profiteering-on-diabetes-drugs-by-sections-of-pharmaceutical-industry/cid/2009774). The Telegraph India.

Mar 29: [Weight-loss drugs cost \$1,000 a month but less than 25 to make. Why do we pay so much?](https://eu.usatoday.com/story/news/health/2024/03/29/ozempic-wegovy-weight-loss-diabetes-drug-cost/73125135007). USA Today.

Mar 29: [Ozempic costs just \$5 to make, a study said. The backlash was swift.](https://qz.com/ozempic-price-backlash-study-sanders-1851374290). Quartz.

Mar 29: [GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable.](https://www.statnews.com/2024/03/29/glp-1-insulin-generics-ozempic-drug-pricing). Stat News.

Mar 29: [Nyt studie: Populær medicin koster alt, alt for meget](https://www.bt.dk/sundhed/nyt-studie-populaer-medicin-koster-alt-alt-for-meget). BT (Denmark).

Mar 28: [Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed](https://www.theguardian.com/global-development/2024/mar/28/drug-companies-diabetes-drugs-medicines-ozempic-trulicity). The Guardian.

Mar 28: [Sanders presses Novo Nordisk over Ozempic, Wegovy prices](https://www.washingtonpost.com/politics/2024/03/28/state-sanctioned-hospital-monopoly-raises-concerns). The Washington Post.

Mar 28: [MSF’s costing study says newer diabetes drugs and insulin pens priced beyond patient reach](https://www.thehindu$businessline.com/companies/msf-costing-study-says-newer-diabetes-drugs-and-insulin-pens-priced-beyond-patient-reach/article67999181.ece). The Hindu.

Mar 28: [Bernie Sanders wants to make Ozempic cheaper](https://www.businessinsider.com/bernie-sanders-ozempic-cheaper-novo-nordisk-2024-3). Business Insider.

Mar 28: [Bernie Sanders implores Novo to cut list prices of Ozempic, Wegovy](https://endpts.com/bernie-sanders-implores-novo-to-cut-list-prices-of-ozempic-wegovy). Endpoints News.

Mar 28: [Costly Ozempic jab, which costs up to \$1,300, can be made for just 5, study claims](https://nypost.com/2024/03/28/lifestyle/ozempic-which-costs-up-to-1300-can-be-made-for-5-study). New York Post.

Mar 28: [High prices on GLP-1 meds, insulin pens raise barriers to access in lower-income countries: MSF](https://www.fiercepharma.com/pharma/high-markups-glp-1s-insulin-pens-present-barriers-access-lower-income-countries-report). Fierce Pharma.

Mar 28: [Amerikanen betalen er bijna 1.000 euro per maand voor, maar afvalmiddel Ozempic kan “voor nog geen 5 dollar” gemaakt worden](https://www.hln.be/medisch/amerikanen-betalen-er-bijna-1-000-euro-per-maand-voor-maar-afvalmiddel-ozempic-kan-voor-nog-geen-5-dollar-gemaakt-worden~a14c2868). Het Laatste Nieuws (Belgium).

Mar 28: [Ozempic makers could be raking in 40,000% profit — study says diabetes drug can be made for \$1/month](https://theprint.in/health/ozempic-makers-could-be-raking-in-40000-profit-study-says-diabetes-drug-can-be-made-for-1-month). The Print.

Mar 28: [Medicamentos modernos para a diabetes são vendidos 400 vezes mais caros do que o necessário, denuncia estudo](https://executivedigest.sapo.pt/noticias/medicamentos-modernos-para-a-diabetes-sao-vendidos-400-vezes-mais-caros-do-que-o-necessario-denuncia-estudo). Sapo (Portugal).

Mar 27: ['Huge markup on prices of new diabetes medicines and insulin pens'](https://timesofindia.indiatimes.com/business/india-business/huge-markup-on-prices-of-new-diabetes-medicines-and-insulin-pens/articleshow/108828024.cms). The Times of India.

Mar 27: [Sanders calls for Novo Nordisk to slash Ozempic, Wegovy prices](https://www.sanders.senate.gov/press-releases/news-sanders-statement-on-outrageous-cost-of-ozempic). Office of Bernie Sanders.

Mar 27: [Novo Nordisk’s \$1,000 diabetes drug Ozempic can be made for less than \$5 a month, study suggests](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html). CNBC.

Mar 27: [Weight-loss drug 'could be profitably made for as little as €4.40 a month'](https://www.irishexaminer.com/business/companies/arid-41362483.html). Irish Examiner.

Mar 27: [Sanders calls for Novo Nordisk to slash Ozempic, Wegovy prices](https://thehill.com/policy/healthcare/4560323-sanders-calls-for-novo-nordisk-slash-ozempic-wegovy-prices). The Hill.

Mar 27: [Ozempic, Novo’s \$1,000 Diabetes Shot, Can Be Made for Under 5 a Month](https://www.bloomberg.com/news/articles/2024-03-27/ozempic-novo-s-1-000-diabetes-drug-can-be-made-for-less-than-5-a-month). Bloomberg.

Mar 27: [Ozempic, the \$1,000 diabetes drug, can be made for less than 5 a month: study](https://ottawacitizen.com/health/ozempic-the-1000-diabetes-drug-can-be-made-for-less-than-5-a-month-study). Ottawa Citizen.


<div style="text-align: center;">
    <h5>2023</h5>
</div>

Nov 29: [Why it’s time to spotlight the harms of supply shortages](https://healthjournalism.org/blog/2023/11/spotlight-the-harms-of-supply-shortages). Association of Health Care Journalists.

Sept 15: [Health subcommittee members at odds over drafted drug shortage legislation](https://www.fiercehealthcare.com/providers/health-subcommittee-members-odds-over-drafted-drug-shortage-legislation). Fierce Healthcare.

Sept 14: [No 'Silver Bullet' for Generic Drug Shortage, House Members Told](https://www.medpagetoday.com/publichealthpolicy/healthpolicy/106345). Medpage Today.

Sept 14: [Partisan divide on drug shortages unresolved after hearing](https://rollcall.com/2023/09/14/partisan-divide-on-drug-shortages-unresolved-after-hearing). Roll Call News.

May 2: [Introducing the 2023 ASHEcon Award Winners](https://www.ashecon.org/awards/introducing-the-2023-ashecon-award-winners). American Society of Health Economists.


<div style="text-align: center;">
    <h5>2022</h5>
</div>

July 22: [Lucro das maiores farmacêuticas cresce 41% na pandemia](https://www.poder360.com.br/coronavirus/lucro-das-maiores-farmaceuticas-cresce-41-na-pandemia). Poder360.

July 22: [Farmacêuticas podiam cobrar menos, diz pesquisadora de Harvard](https://www.poder360.com.br/coronavirus/farmaceuticas-podiam-cobrar-menos-diz-pesquisadora-de-harvard). Poder360.

July 12: [How Many Variants And Deaths Are We Willing To Accept, Before We Protect The Whole World?](https://www.forbes.com/sites/madhukarpai/2022/07/12/how-many-variants-and-deaths-are-we-willing-to-accept-before-we-protect-the-whole-world). Forbes.

June 17: [W.T.O. countries agree to a limited relaxing of patent protections on coronavirus vaccines](https://www.nytimes.com/2022/06/17/business/wto-covid-vaccine-patent.html). New York Times.

May 25: [Behind Pfizer's new not-for-profit deal on patented vaccines and drugs](https://www.devex.com/news/behind-pfizer-s-new-not-for-profit-deal-on-patented-vaccines-and-drugs-103323). Devex.

Apr 4: [African clinical trial denied access to key COVID drug Paxlovid](https://www.nature.com/articles/d41586-022-00919-5). Nature.

Feb 28: [Paxlovid e Molnupiravir, pillola anti-Covid: il ricatto delle case farmaceutiche ai sistemi sanitari](https://www.corriere.it/dataroom-milena-gabanelli/paxlovid-molnupiravir-pillola-anti-covid-ricatto-case-farmaceutiche-sistemi-sanitari-tutti-guadagni/2fdb32ba-97d7-11ec-97aa-535db4de4386-va.shtml). Corriere della Sera.



<div style="text-align: center;">
    <h5>2021</h5>
</div>

Oct 4: [Merck’s Covid-19 pill may be a game-changer, but questions are already being raised about cost](https://www.statnews.com/pharmalot/2021/10/04/covid19-merck-molnupiravir-ridgeback-patents). STAT.

Oct 19: [WHO-led programme aims to buy antiviral COVID-19 pills for \$10 -document](https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-who-led-programme-aims-buy-antiviral-covid-19-pills-10-document-2021-10-19). Reuters.

Oct 17: [Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?](https://www.nytimes.com/2021/10/17/health/covid-treatment-access-molnupiravir.html). New York Times.

Oct 7: [Merck slammed for 4,000% markup of taxpayer-funded COVID-19 drug](https://www.salon.com/2021/10/07/entirely-unsurprising-merck-slammed-for-4000-markup-of-taxpayer-funded-19_partner). Salon.

Oct 6: [Buyers clamor for Merck's COVID-19 antiviral molnupiravir, but pricing is already controversial](https://www.fiercepharma.com/pharma/amid-controversy-over-its-price-rush-to-secure-merck-and-ridgeback-s-covid-19-drug). Fierce Pharma.

Oct 6: [Covid pill makers accused of selling drug to US at 40 times what it costs to make despite govt funding](https://www.independent.co.uk/news/world/americas/us-merck-covid-pill-cost-b1933100.html). Independent.

Oct 5: [Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What It Costs to Make](https://theintercept.com/2021/10/05/covid-pill-drug-pricing-merck-ridgeback). The Intercept.

Oct 4: [Why Merck’s Molnupiravir banks heavily on India](https://www.fortuneindia.com/enterprise/why-mercks-new-covid-19-drug-banks-on-india-2/105949). Fortune India.

Oct 4: [Indian Generic Companies Are Ready to Make Merck’s COVID-19 Antiviral Pill](https://healthpolicy-watch.org/generic-companies-are-ready-to-make-mercks-covid-19-pill). Health Policy Watch.


<div style="text-align: center;">
    <h5>2020</h5>
</div>

Sept 29: [La insulina podría ser más barata sin que las farmacéuticas pierdan ganancias, según estudio](https://www.elespectador.com/salud/la-insulina-podria-ser-mas-barata-sin-que-las-farmaceuticas-pierdan-ganancias-segun-estudio-article-815051). El Espectador.

Aug 16: [States are trying to cap the price of insulin. Pharmaceutical companies are pushing back](https://www.nbcnews.com/news/us-news/states-are-trying-cap-price-insulin-pharmaceutical-companies-are-pushing-n1236766). NBC.


<div style="text-align: center;">
    <h5>2019</h5>
</div>

Nov 15: [Elizabeth Warren’s First Term Plan for Reducing Health Care Costs in America and Transitioning to Medicare for All](https://medium.com/@teamwarren/my-first-term-plan-for-reducing-health-care-costs-in-america-and-transitioning-to-medicare-for-all-8d45dd993872). Medium.

Oct 8: [Why would the government make its own drugs?](https://www.newstatesman.com/politics/health/2019/10/why-would-government-make-its-own-drugs). New Statesman.

June 25: [Why Insulin Defies The Normal Rules Of Economics And Keeps Getting More Expensive](https://www.wbur.org/news/2019/06/25/why-insulin-defies-the-normal-rules-of-economics-and-keeps-getting-more-expensive). WBUR.




<div style="text-align: center;">
    <h5>2018</h5>
</div>

Sept 25: [Insulin prices could be much lower and drug makers would still make healthy profits](https://www.statnews.com/pharmalot/2018/09/25/insulin-prices-profits-diabetes). STAT.



<div style="text-align: center;">
    <h5>2017</h5>
</div>
May 31: [The drug rebellion fighting big pharma to save the NHS millions](https://www.newscientist.com/article/mg23431281-100-big-pharma-makes-a-killing-off-deadly-diseases-what-can-stop-them). New Scientist.

May 16: [EU starts investigation of Aspen's cancer drug pricing](https://www.pmlive.com/pharma_news/eu_starts_investigation_of_aspens_cancer_drug_pricing_1192899). PmLiVE.

Jan 30: [Price hikes for some generic cancer drugs in the UK have skyrocketed](https://www.statnews.com/pharmalot/2017/01/30/cancer-generics-drug-prices). STAT.

Jan 29: [Cancer drugs price rise 'costing NHS millions'](https://www.bbc.com/news/health-38769625). BBC.

Jan 28: [Drugs firms are accused of putting cancer patients at risk over price hikes](https://www.theguardian.com/society/2017/jan/28/nhs-drug-firms-cancer-patients-at-risk-prices-inflated). The Guardian.



